Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q2KHT3
UPID:
CL16A_HUMAN
Alternative names:
C-type lectin domain family 16 member A
Alternative UPACC:
Q2KHT3; O15058; Q6ZTB2
Background:
Protein CLEC16A, also known as C-type lectin domain family 16 member A, plays a pivotal role in cellular processes, particularly in mitophagy, the selective autophagy necessary for mitochondrial quality control. It functions through the RNF41/NRDP1-PRKN pathway, regulating autophagosome-lysosome fusion during late mitophagy and protecting RNF41/NRDP1 from proteasomal degradation. This protein is crucial for maintaining mitochondrial health and beta cell functions.
Therapeutic significance:
CLEC16A is linked to Type 1 diabetes mellitus, a disorder of glucose homeostasis leading to severe complications affecting eyes, kidneys, nerves, and blood vessels. Variants affecting CLEC16A have been associated with the disease, highlighting its potential as a target for therapeutic strategies aimed at improving beta cell function and mitigating disease progression.